Why Declining Clinical Studies Can Be a Good Business Decision for Your Site

By Doug Cavers | Associate Director of Clinical Operations, ClinEdge
October 6th, 2016

Summary: Taking on a study that doesn’t fit your site’s capabilities can hurt your reputation. Learn why it makes sense to decline certain studies.

Estimated reading time: 2 minutes

At any given time, there are hundreds of clinical trial sponsors actively searching for additional investigators. However, only a portion of these studies will be a good match for your research site, and an even smaller number of these acceptable studies are beneficial to your site’s big-picture goals. With a wide and diverse array of studies available, research sites should prioritize a study’s worth, and pass on the less-desirable options.

Over time, the choices you make on your study selection can have significant impacts on your site. Going after the right studies helps your site build experience, grow its business and develop positive relationships among leading sponsors and CROs. Taking on studies that aren’t a good fit for your site’s capabilities will divert time and resources away from your key business objectives. It can even damage your site’s reputation across the industry as a whole. Knowing which studies your site should decline is crucial to your long-term growth.

Attend our webinar on October 18, 2016 titled, Learn When to Accept and Decline Study Opportunities: It’s OK to Say No, and learn the answers to these two questions:

  1. Why do smart sites only accept certain study opportunities?
  2. How do sites determine which trials they should decline?

During the webinar, we’ll discuss the strategic benefits of declining clinical trials that do not fit your site’s growth plan. You’ll learn the reason why taking on studies outside of your site’s capabilities can be detrimental to its reputation. You will take away an understanding of the factors to consider when deciding whether to decline or accept a certain trial, particularly in terms of the study’s financial incentives, burden on your staff and compatibility with your site’s resources. Finally, you’ll receive tips on using strategic declining methods to tailor your site’s pipeline for continued success.

Whether you are a single-investigator private practice, a multi-specialty dedicated study center, or a large hospital-based research division, strategically declining studies is important to your site’s growth. Applying key principles to your process for declining potentially detrimental study opportunities allows you to better prepare for opportunities that will build on your experience or expand your business into exciting new therapeutic areas. You will be more confident in deciding which studies deserve your time and attention and which studies you should decline. For small and big research sites alike, it’s okay to say no!

About the Author

Doug is an Associate Director of Clinical Operations at ClinEdge. He works with both sites and sponsors/CROs in a variety of capacities to optimize and streamline the site selection process. Doug and his team provide personalized business development to a network of elite research sites and are constantly finding new ways to make site processes operationally efficient. He holds a bachelor’s degree in English from Tufts University.

Website: ClinEdge

You May Also Be Interested In:

20 Questions to Help Your Clinical Research Site Get Noticed

Use these questions to unlock your clinical research site's potential and stand out to sponsors, CROs and study participants.

Read more »

How to Attract Sponsors and CROs: 9 Resources for Sites

Learn to promote your site to sponsors and CROs, build your study pipeline and develop your business strategy using these nine resources.

Read more »

Leave a comment or ask a question:

(Your email address will not be published.)

Write for us!

Are you interested in writing about a topic in clinical research? We'd love to have you become a guest contributor for the Forte Clinical Research Blog.

Learn more